Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)

被引：5

作者：

Wei, Andrew H. ^{[1
,2
]}

Breccia, Massimo ^{[3
]}

Ooi, Melissa ^{[4
]}

Romero, Maria Teresa Cedena ^{[5
]}

Ciceri, Fabio ^{[6
]}

Erba, Harry P. ^{[7
]}

Gaur, Anil ^{[8
]}

Sechaud, Romain ^{[9
]}

Halilovic, Ensar ^{[10
]}

Kuenzle, Brigitte ^{[9
]}

Fabre, Claire ^{[9
]}

Porkka, Kimmo ^{[11
]}

机构：

[1] Alfred Hosp, Melbourne, Vic, Australia

[2] Monash Univ, Melbourne, Vic, Australia

[3] Sapienza Univ Rome, Rome, Italy

[4] Natl Univ Canc Inst, Singapore, Singapore

[5] Hosp Univ 12 Octubre, Inst Invest Sanitaria Imas12, Madrid, Spain

[6] IRCCS Osped San Raffaele, Milan, Italy

[7] Duke Univ, Blood Canc Ctr, Hematol Malignancies Clin, Durham, NC USA

[8] Novartis Healthcare Pvt Ltd, Hyderabad, India

[9] Novartis Pharmaceut, Basel, Switzerland

[10] Novartis Inst BioMed Res, Cambridge, MA USA

[11] Univ Helsinki, Cent Hosp, Ctr Canc, Helsinki, Finland

来源：

关键词：

D O I：

10.1182/blood-2021-144650

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1283

引用

页数：4

共 21 条